GDC-0425

GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignancies[1][2].

Product Specifications

CAS Number

[1200129-48-1]

Product Name Alternative

RG-7602

UNSPSC

12352005

Target

Checkpoint Kinase (Chk)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gdc-0425.html

Purity

99.60

Solubility

H2O : 25 mg/mL (ultrasonic; adjust pH to 3 with HCl)

Smiles

N#CC1=NC=C2C(C3=CC=CN=C3N2)=C1OC4CCN(CC)CC4

Molecular Formula

C18H19N5O

Molecular Weight

321.38

References & Citations

[1]Xiao Ding, et al. A supported liquid extraction LC-MS/MS method for determination of concentrations of GDC-0425, a small molecule Checkpoint kinase 1 inhibitor, in human plasma. Biomed Chromatogr. 2016 Dec;30 (12) :1984-1991.|[2]Jeffrey R Infante, et al. Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. Clin Cancer Res. 2017 May 15;23 (10) :2423-2432.|[3]Ho-June Lee, et al. Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells. Mol Cancer Ther. 2017 Apr;16 (4) :694-704.